Castellano | Euskara | Français | English
Drug Assessment Reports
Share it
Drug Assessment Reports
Herein you will find both a short report and a full text document for each new drug assessed.
| What is DAR? | About us | Conflicts of interest | Reports | Search | Subscribe | Home |
Latest Drug Assessment Reports published:
Year 2012
- No 3 Chondroitin sulfate / Glucosamine (Droglican®) in osteoarthritis
- No 2 Denosumab (Prolia®) for osteoporosis
- No 1 Pitavastatin (Alipzal®, Livazo®) in dyslipidemia
Year 2011
- No 14 Moxifloxacin 0.5 % eye drop solution (Vigamox®) for bacterial conjunctivitis
- No 13 Colesevelam (Cholestagel®) in primary hypercholesterolaemia
- No 12 Sublingual fentanyl citrate (Abstral®) For breakthrough pain in cancer patients
- No 11 Liraglutide (Victoza®) in type 2 diabetes
- No 10 Ciclesonide (Alvesco®) in asthma
- No 9 Dutasteride/Tamsulosin (Duodart®) in benign prostatic hyperplasia
- No 8 Saxagliptin (Onglyza®) in type 2 diabetes
- No 7 Bazedoxifene (Conbriza®) and osteoporosis
- No 6 Tafluprost (Saflutan ®) for elevated intraocular pressure in open-angle glaucoma and ocular hypertension
- No 5 Dronedarone (Multaq ®) for non-permanent atrial fibrillation
- No 4 Rosuvastatin (Crestor®)
- No 3 Ranolazine (Ranexa®)
- No 2 Grass pollen allergen Phleum pratense (Grazax®)
- No 1 Indacaterol (Onbrez breezhaler®)
Year 2010
- No 7 Azithromycin ophthalmic solution (Azydrop®)
- No 6 Silodosin (Urorec®, Silodyx®)
- No 5 Methylnaltrexone (Relistor®)
- No 4 Cilostazol (Ekistol®, Pletal®)
- No 3 Agomelatine (Valdoxan®)
- No 2 Amlodipin + Atorvastatin (Caduet®, Astucor®)
- No 1 Nicotinic acid / Laropiprant (Tredaptive®)
